Drew Neavin

Drew Neavin is a Research Officer at the Garvan Institute of Medical Research, a position they have held since April 2019.3 They are a driven researcher dedicated to enhancing our understanding of the variation in patient response to medication through the use of biological measures including genomics, epigenomics, proteomics, metabolomics, and microbiome.3

Neavin has an extensive background in medical research:

• They hold a PhD in Molecular Pharmacology and Experimental Therapeutics from Mayo Clinic Graduate School of Biomedical Sciences (2014-2018).3
• Prior to their current role, they worked as a Postdoctoral Research Fellow at the Mayo Clinic from December 2018.3
• Their earlier education includes a Bachelor of Arts in Spanish Language and Literature, a Bachelor of Science in Population and Molecular Genetics, and a minor in Mathematics from Colorado State University (2009-2013).3

Neavin's research focuses on population genomics, single-cell analysis, and context-specific QTL investigation.4 They have published several papers in prestigious journals, including Nature Communications and Genome Biology.5 Recently, Neavin was recognized as a winner of the #100MillionCellChallenge, highlighting their innovative work in the field.2

Their research contributions span various areas, including:

• Single-cell eQTL analysis in fibroblasts and induced pluripotent stem cells.1
• Shared genetic susceptibility between trigger finger and carpal tunnel syndrome.1
• Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration.5

Neavin is proficient in both English (native) and Spanish (professional working proficiency).3